Fig. 7: ARAC reduces tumor growth and prolongs survival of mice bearing KLN-205 murine lung tumors.
From: Development of a nanoparticle-based immunotherapy targeting PD-L1 and PLK1 for lung cancer treatment
a DBA/2 mice were injected with 500,000 KLN-205 cells in 100 μL PBS on the right flank. 13 days post inoculation, mice were grouped (n = 7) and treated with saline, ICIs (PD-1 and CTLA-4 antibodies – i.p. 200 μg/dose and 100 μg/dose respectively – for 6 doses), or ARAC (i.v. 50 mg/kg for 4 doses). a KLN-205 tumor growth; blue arrows specify ARAC dosing days, red arrows specify ICI dosing days. Data presented as mean + SEM; **P = 0.0011 for ARAC vs. saline, **P = 0.0041 for ARAC vs. ICIs (mixed model Two-Way repeated measures ANOVA with Tukey’s correction for multiple comparisons). b Kaplan–Meier Survival curve. *P = 0.0101 for ARAC vs. saline, *P = 0.0231 for ARAC vs. ICIs (Log-rank Mantel–Cox test). Source data are provided as a Source Data file.
